NEOPLASM METASTASIS

This global Phase 3 study is testing whether adding an experimental drug called LY3537982 (olomorasib) to standard cancer treatments works better than standard treatments alone for people with untreated advanced non-small cell lung cancer. The trial is specifically for patients w…

This is the first human trial of a new experimental cancer drug called LY4175408. It is designed to target and deliver a toxic payload specifically to cancer cells that have a certain marker (PTK7). The study will test the drug's safety, side effects, and early signs of effective…

This study is testing a new targeted radiation treatment called LY4257496 for people with advanced cancers that have a specific protein (GRPR). The main goals are to find a safe dose and see if the treatment helps shrink tumors. It is for adults with certain advanced breast, pros…

This study is testing whether adding an experimental drug called Tersolisib to standard breast cancer medications works better for people with advanced hormone-positive breast cancer that has a specific genetic change called PIK3CA mutation. The trial will involve about 920 adult…

This early-stage study is testing a new drug called LOXO-435 for people with advanced solid tumors, including bladder cancer, that have a specific genetic change (FGFR3). The main goals are to find a safe dose, understand side effects, and see if the drug can shrink tumors. The s…

This large, two-part study is testing a new drug called sofetabart mipitecan for people with advanced ovarian, fallopian tube, or peritoneal cancer. Part A is for people whose cancer has stopped responding to standard platinum chemotherapy. Part B is for people whose cancer still…

This study is testing whether adding a new drug called vepugratinib to two existing cancer drugs works better for people with advanced bladder cancer that has spread and has a specific genetic change (FGFR3). About 450 adults who haven't had treatment for their advanced cancer wi…

This early-stage study is testing a new combination of three drugs for people with advanced head and neck cancer that has returned or spread. The main goal is to find the safest and most effective dose of the new drug, Zanzalintinib, when given with two existing cancer drugs. Res…

This study aims to understand why prostate cancer progresses slowly in some men but aggressively in others. Researchers will follow 3,000 newly diagnosed patients in France and the Caribbean, collecting information about their genetics, lifestyle, and environment. The goal is to …

This study observes how patients with advanced breast cancer respond to an existing medication called trastuzumab deruxtecan in real-world settings. Researchers will track 800 patients in Germany to understand how long the treatment works before patients need new therapy and how …